Status:
COMPLETED
Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3
Lead Sponsor:
Ain Shams University
Conditions:
Chronic Kidney Disease stage3
Contrast-induced Nephropathy
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study will determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury in chronic kidney disease patients Stage 3 undergoing percutaneous coronary inte...
Detailed Description
In this randomised non blinded clinical trial, Investigators will study 120 CKD patients undergoing PCI to determine the renoprotective effect of febuxostat in prevention of contrast induced acute kid...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old .
- Patients under treatment of high dose statin(Atorvastatin (40-80 mg/day) .
- Glomerular filtration rate=30-59ml/min.
- Undergoing coronary PCI.
Exclusion
- Patients under treatment with febuxostat. Known allergy to febuxostat. High osmolar contrast media during the procedure .
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05264584
Start Date
December 1 2020
End Date
February 1 2022
Last Update
March 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams university hospitals
Cairo, Egypt, 1181